PDL BioPharma Inc.

(PDLI) Trade

By |

Profile

PDL BioPharma Inc acquires and manages a portfolio of companies, products, royalty agreements and debt facilities in the biotech, pharmaceutical and medical device industries. The operating segments of the company are Pharmaceutical and Medical Devices, of which key revenue is derived from the Pharmaceutical segment. The Pharmaceutical segment consists of revenue derived from branded prescription medicine products sold under the name Tekturna and Tekturna HCT in the U.S, and Rasilez and Rasilez HCT in the rest of the world (collectively, the Noden Products). Geographically, the company operates in Europe, North America, Asia and Other countries, of which prime revenue is generated from Asia and North America.

Contact Information

Website: www.pdl.com
Email: ir@pdl.com
Main Phone: +1 775 832-8500
Address: 932 Southwood Boulevard
State: NV
City / Town: Incline Villiage
Country: USA
Postal Code: 89451

Issuer Information

Exchange: NGS
CEO: Dominique Monnet
Employees: 107
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

Profile

PDL BioPharma Inc acquires and manages a portfolio of companies, products, royalty agreements and debt facilities in the biotech, pharmaceutical and medical device industries. The operating segments of the company are Pharmaceutical and Medical Devices, of which key revenue is derived from the Pharmaceutical segment. The Pharmaceutical segment consists of revenue derived from branded prescription medicine products sold under the name Tekturna and Tekturna HCT in the U.S, and Rasilez and Rasilez HCT in the rest of the world (collectively, the Noden Products). Geographically, the company operates in Europe, North America, Asia and Other countries, of which prime revenue is generated from Asia and North America.

Contact Information

Website: www.pdl.com
Email: ir@pdl.com
Main Phone: +1 775 832-8500
Address: 932 Southwood Boulevard
State: NV
City / Town: Incline Villiage
Country: USA
Postal Code: 89451

Issuer Information

Exchange: NGS
CEO: Dominique Monnet
Employees: 107
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

$ 3.12 $ 0.07 (2.30%)
Last Price 3.12 Change $ 0.07 Change % 2.30 Tick N/A
Bid 2.40 Bid Size 200.00 Ask 3.19 Ask Size 800.00
Open 3.06 High 3.16 Low 3.04 Prev Close 3.05
Last Trade Volume 955,399 52 Wk Hi 3.89 52 Wk Low 2.06
Market Cap 356.3 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 114,202,671.00 EPS (TTM) 0.30 PE Ratio 9.50 Exchange NGS
  Last 3 Mo Last 12 Mo
Number of Insider Trades 7 12
Number of Buys 7 8
Number of Sells 0 4
Net Activity 380436 427668
Last 10 Buys Shares
Peter S. Garcia 1,000
Peter S. Garcia 1,000
Peter S. Garcia 1,000
Peter S. Garcia 1,000
Peter S. Garcia 1,000
Peter S. Garcia 1,000
Peter S. Garcia 1,000
Peter S. Garcia 1,000
Peter S. Garcia 1,000
Steffen Pietzke 1,000
Last 10 Sell Shares
N/A 0
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 3 3 3 3
Low Target Price Estimate 3 3 3 3
Mean Target Price Estimate 3 3 3 3
Standard Deviation 0 0 0 0
Date of Most Recent Estimate 03/12/18 03/12/18 03/12/18 03/12/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 0 0 0 0
Moderate Buy 0 0 0 0
Hold 1 1 1 1
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 3 3 3 3